These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37210008)

  • 1. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.
    Rudin CM; Balli D; Lai WV; Richards AL; Nguyen E; Egger JV; Choudhury NJ; Sen T; Chow A; Poirier JT; Geese WJ; Hellmann MD; Forslund A
    J Thorac Oncol; 2023 Sep; 18(9):1222-1232. PubMed ID: 37210008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
    Nguyen EM; Taniguchi H; Chan JM; Zhan YA; Chen X; Qiu J; de Stanchina E; Allaj V; Shah NS; Uddin F; Manoj P; Liu M; Cai SF; Levine R; Quintanal-Villalonga Á; Sen T; Chow A; Rudin CM
    J Thorac Oncol; 2022 Aug; 17(8):1014-1031. PubMed ID: 35691495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
    Antonia SJ; López-Martin JA; Bendell J; Ott PA; Taylor M; Eder JP; Jäger D; Pietanza MC; Le DT; de Braud F; Morse MA; Ascierto PA; Horn L; Amin A; Pillai RN; Evans J; Chau I; Bono P; Atmaca A; Sharma P; Harbison CT; Lin CS; Christensen O; Calvo E
    Lancet Oncol; 2016 Jul; 17(7):883-895. PubMed ID: 27269741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.
    Dowlati A; Abbas A; Chan T; Henick B; Wang X; Doshi P; Fu P; Patel J; Kuo F; Chang H; Balli D
    JCO Precis Oncol; 2022 Aug; 6():e2200257. PubMed ID: 36044718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
    Ready N; Farago AF; de Braud F; Atmaca A; Hellmann MD; Schneider JG; Spigel DR; Moreno V; Chau I; Hann CL; Eder JP; Steele NL; Pieters A; Fairchild J; Antonia SJ
    J Thorac Oncol; 2019 Feb; 14(2):237-244. PubMed ID: 30316010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
    Xie M; Vuko M; Rodriguez-Canales J; Zimmermann J; Schick M; O'Brien C; Paz-Ares L; Goldman JW; Garassino MC; Gay CM; Heymach JV; Jiang H; Barrett JC; Stewart RA; Lai Z; Byers LA; Rudin CM; Shrestha Y
    Mol Cancer; 2024 May; 23(1):115. PubMed ID: 38811992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
    Horn L; Reck M; Spigel DR
    Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab for the treatment of small cell lung cancer.
    Simeone E; Grimaldi AM; Festino L; Trojaniello C; Vitale MG; Vanella V; Curvietto M; Ascierto PA
    Expert Rev Respir Med; 2020 Jan; 14(1):5-13. PubMed ID: 31622114
    [No Abstract]   [Full Text] [Related]  

  • 9. A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
    Malhotra J; Nikolinakos P; Leal T; Lehman J; Morgensztern D; Patel JD; Wrangle JM; Curigliano G; Greillier L; Johnson ML; Ready N; Robinet G; Lally S; Maag D; Valenzuela R; Blot V; Besse B
    J Thorac Oncol; 2021 Sep; 16(9):1559-1569. PubMed ID: 33652156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
    Reck M; Ciuleanu TE; Lee JS; Schenker M; Zurawski B; Kim SW; Mahave M; Alexandru A; Peters S; Pluzanski A; Caro RB; Linardou H; Burgers JA; Nishio M; Martinez-Marti A; Azuma K; Axelrod R; Paz-Ares LG; Ramalingam SS; Borghaei H; O'Byrne KJ; Li L; Bushong J; Gupta RG; Grootendorst DJ; Eccles LJ; Brahmer JR
    J Thorac Oncol; 2023 Aug; 18(8):1055-1069. PubMed ID: 37146754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
    Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells.
    Chi W; Zhang L; Wang X; Li J; Li F; Ma Y; Zhang Q
    Invest New Drugs; 2022 Aug; 40(4):709-717. PubMed ID: 35438354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
    Hellmann MD; Callahan MK; Awad MM; Calvo E; Ascierto PA; Atmaca A; Rizvi NA; Hirsch FR; Selvaggi G; Szustakowski JD; Sasson A; Golhar R; Vitazka P; Chang H; Geese WJ; Antonia SJ
    Cancer Cell; 2018 May; 33(5):853-861.e4. PubMed ID: 29731394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
    Cooper MR; Alrajhi AM; Durand CR
    Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
    Vos JL; Elbers JBW; Krijgsman O; Traets JJH; Qiao X; van der Leun AM; Lubeck Y; Seignette IM; Smit LA; Willems SM; van den Brekel MWM; Dirven R; Baris Karakullukcu M; Karssemakers L; Klop WMC; Lohuis PJFM; Schreuder WH; Smeele LE; van der Velden LA; Bing Tan I; Onderwater S; Jasperse B; Vogel WV; Al-Mamgani A; Keijser A; van der Noort V; Broeks A; Hooijberg E; Peeper DS; Schumacher TN; Blank CU; de Boer JP; Haanen JBAG; Zuur CL
    Nat Commun; 2021 Dec; 12(1):7348. PubMed ID: 34937871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
    Spigel DR; Socinski MA
    J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Signatures for Responses to Checkpoint Blockade in Small-Cell Lung Cancer in Second-Line Therapy Do Not Predict Responses in First-Line Patients.
    Thompson JC; Tilsed C; Davis C; Gupta A; Melidosian B; Sun C; Kallen ME; Timmers C; Langer CJ; Albelda SM
    Cancers (Basel); 2024 Aug; 16(16):. PubMed ID: 39199568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
    Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
    Friedman CF; Spencer C; Cabanski CR; Panageas KS; Wells DK; Ribas A; Tawbi H; Tsai K; Postow M; Shoushtari A; Chapman P; Karakunnel J; Bucktrout S; Gherardini P; Hollmann TJ; Chen RO; Callahan M; LaVallee T; Ibrahim R; Wolchok J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.